Your browser is no longer supported. Please, upgrade your browser.
ACRS Aclaris Therapeutics, Inc. daily Stock Chart
ACRS [NASD]
Aclaris Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.45 Insider Own3.90% Shs Outstand41.62M Perf Week32.00%
Market Cap75.40M Forward P/E- EPS next Y-1.48 Insider Trans0.00% Shs Float38.12M Perf Month25.32%
Income-101.60M PEG- EPS next Q-0.36 Inst Own82.60% Short Float3.59% Perf Quarter72.17%
Sales4.40M P/S17.14 EPS this Y-10.10% Inst Trans-0.46% Short Ratio2.56 Perf Half Y6.45%
Book/sh1.40 P/B1.41 EPS next Y-3.50% ROA- Target Price- Perf Year-10.00%
Cash/sh2.07 P/C0.95 EPS next 5Y- ROE- 52W Range0.70 - 2.38 Perf YTD4.76%
Dividend- P/FCF- EPS past 5Y-57.10% ROI-158.70% 52W High-15.97% Beta1.17
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin5.80% 52W Low185.71% ATR0.18
Employees77 Current Ratio4.00 Sales Q/Q7.70% Oper. Margin- RSI (14)68.22 Volatility10.60% 12.14%
OptionableYes Debt/Eq0.19 EPS Q/Q44.30% Profit Margin- Rel Volume2.85 Prev Close1.98
ShortableYes LT Debt/Eq0.18 EarningsMay 26 AMC Payout- Avg Volume534.95K Price2.00
Recom1.60 SMA2023.25% SMA5036.66% SMA20037.10% Volume135,580 Change1.01%
Oct-22-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19Initiated SVB Leerink Outperform $13
Mar-28-18Resumed Leerink Partners Outperform $52
Feb-09-18Initiated Guggenheim Buy $53
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
Jul-08-20 08:43AM  
Jul-07-20 04:01PM  
Jun-26-20 02:30PM  
Jun-18-20 10:12AM  
Jun-17-20 10:37AM  
07:01AM  
Jun-03-20 07:00AM  
May-26-20 04:01PM  
May-12-20 10:47AM  
May-08-20 12:00PM  
May-07-20 04:01PM  
May-06-20 12:30PM  
Apr-09-20 06:13AM  
Apr-06-20 12:00PM  
Apr-01-20 11:07AM  
Mar-31-20 04:01PM  
Mar-17-20 02:46AM  
Feb-25-20 04:01PM  
Feb-24-20 07:31AM  
Feb-19-20 05:00PM  
Feb-10-20 07:00AM  
Jan-13-20 05:03PM  
Jan-10-20 07:13AM  
05:40AM  
Jan-09-20 04:27PM  
Jan-08-20 08:00AM  
Dec-24-19 12:00PM  
Dec-12-19 10:33AM  
Nov-27-19 03:23PM  
Nov-21-19 11:39AM  
Nov-18-19 05:34PM  
Nov-17-19 07:14AM  
Nov-12-19 04:01PM  
Nov-07-19 04:01PM  
Oct-31-19 04:01PM  
Oct-29-19 10:33AM  
Oct-25-19 07:12AM  
Oct-24-19 04:01PM  
Oct-17-19 09:46AM  
Oct-14-19 10:28AM  
Oct-11-19 11:46AM  
Oct-10-19 04:02PM  
Oct-09-19 07:58AM  
Oct-08-19 05:01PM  
01:42PM  
Oct-07-19 07:25AM  
Oct-06-19 10:00AM  
Oct-03-19 07:28AM  
Sep-30-19 12:15PM  
10:44AM  
Sep-28-19 06:30PM  
10:00AM  
Sep-27-19 08:15PM  
03:00PM  
12:21PM  
11:00AM  
10:36AM  
Sep-26-19 04:45PM  
04:45PM  
11:17AM  
08:19AM  
Sep-25-19 08:48PM  
03:38PM  
03:15PM  
11:00AM  
10:35AM  
09:00AM  
Sep-24-19 09:10PM  
03:15PM  
03:09PM  
01:05PM  
Sep-23-19 10:34AM  
09:35AM  
Sep-20-19 03:00PM  
11:31AM  
11:00AM  
10:44AM  
Sep-19-19 07:40PM  
01:30PM  
11:30AM  
Sep-18-19 07:51PM  
05:45PM  
12:23PM  
10:42AM  
Sep-17-19 08:49PM  
02:45PM  
12:29PM  
11:15AM  
07:23AM  
07:00AM  
Sep-16-19 04:55PM  
04:15PM  
10:41AM  
09:38AM  
09:35AM  
09:14AM  
Sep-14-19 07:02AM  
Sep-13-19 03:45PM  
03:15PM  
03:00PM  
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.